Fifteen years of the Australian imaging, biomarkers and lifestyle (AIBL) study: Progress and observations from 2,359 older adults spanning the spectrum from cognitive normality to Alzheimer\u27s disease by Fowler, Christopher et al.
Edith Cowan University 
Research Online 
ECU Publications Post 2013 
2021 
Fifteen years of the Australian imaging, biomarkers and lifestyle 
(AIBL) study: Progress and observations from 2,359 older adults 
spanning the spectrum from cognitive normality to Alzheimer's 
disease 
Christopher Fowler 
Stephanie R. Rainey-Smith 
Edith Cowan University 
Sabine Bird 
Edith Cowan University 
Julia Bomke 
Pierrick Bourgeat 
See next page for additional authors 
Follow this and additional works at: https://ro.ecu.edu.au/ecuworkspost2013 
 Part of the Diseases Commons, and the Neurosciences Commons 
10.3233/ADR-210005 
Fowler, C., Rainey-Smith, S. R., Bird, S., Bomke, J., Bourgeat, P., Brown, B. M., ... Ames, D. (2021). Fifteen years of the 
Australian imaging, biomarkers and lifestyle (AIBL) study: Progress and observations from 2,359 older adults 
spanning the spectrum from cognitive normality to Alzheimer's disease. Journal of Alzheimer's Disease Reports, 
5(1), 443-468. https://doi.org/10.3233/ADR-210005 
This Journal Article is posted at Research Online. 
https://ro.ecu.edu.au/ecuworkspost2013/10436 
Authors 
Christopher Fowler, Stephanie R. Rainey-Smith, Sabine Bird, Julia Bomke, Pierrick Bourgeat, Belinda M. 
Brown, Samantha C. Burnham, Ashley I. Bush, Carolyn Chadunow, Steven Collins, James Doecke, Vincent 
Doré, Kathryn A. Ellis, Lis Evered, Amir Fazlollahi, Jurgen Fripp, Samantha L. Gardener, Simon Gibson, 
Robert Grenfell, Elise Harrison, Richard Head, Liang Jin, Adrian Kamer, Fiona Lamb, Nicola T. 
Lautenschlager, Simon M. Laws, Qiao-Xin Li, Lucy Lim, Yen Ying Lim, Andrea Louey, S. Lance Macaulay, 
Lucy Mackintosh, Ralph N. Martins, Paul Maruff, Colin L. Masters, Simon McBride, Lidija Milicica, 
Madeline Peretti, Kelly Pertile, Tenielle Porter, Morgan Radler, Alan Rembach, Joanne Robertson, Mark 
Rodrigues, Christopher C. Rowe, Rebecca Rumble, Olivier Salvado, Greg Savage, Brendan Silbert, 
Magdalene Soh, Hamid R. Sohrabi, Kevin Taddei, Tania Taddei, Christine Thai, Brett Trounson, Regan 
Tyrrell, Michael Vacher, Shiji Varghese, Victor L. Villemagne, Michael Weinborn, Michael Woodward, Ying 
Xia, David Ames, and AIBL Investigators 
This journal article is available at Research Online: https://ro.ecu.edu.au/ecuworkspost2013/10436 





Fifteen Years of the Australian Imaging,
Biomarkers and Lifestyle (AIBL) Study:
Progress and Observations from 2,359
Older Adults Spanning the Spectrum from
Cognitive Normality to Alzheimer’s Disease
Christopher Fowlera,1, Stephanie R. Rainey-Smithb,c,d,e,1, Sabine Birdb,c, Julia Bomkef ,
Pierrick Bourgeatf , Belinda M. Brownc,d, Samantha C. Burnhamf, Ashley I. Busha,
Carolyn Chadunowa, Steven Collinsa, James Doeckef,g, Vincent Doréf,h, Kathryn A. Ellisa,i,j,
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Abstract.
Background: The Australian Imaging, Biomarkers and Lifestyle (AIBL) Study commenced in 2006 as a prospective study
of 1,112 individuals (768 cognitively normal (CN), 133 with mild cognitive impairment (MCI), and 211 with Alzheimer’s
disease dementia (AD)) as an ‘Inception cohort’ who underwent detailed assessments every 18 months. Over the past decade,
an additional 1247 subjects have been added as an ‘Enrichment cohort’ (as of 10 April 2019).
Objective: Here we provide an overview of these Inception and Enrichment cohorts of more than 8,500 person-years of
investigation.
Methods: Participants underwent reassessment every 18 months including comprehensive cognitive testing, neuroimaging
(magnetic resonance imaging, MRI; positron emission tomography, PET), biofluid biomarkers and lifestyle evaluations.
Results: AIBL has made major contributions to the understanding of the natural history of AD, with cognitive and biological
definitions of its three major stages: preclinical, prodromal and clinical. Early deployment of A-amyloid and tau molecular
PET imaging and the development of more sensitive and specific blood tests have facilitated the assessment of genetic and
environmental factors which affect age at onset and rates of progression.
Conclusion: This fifteen-year study provides a large database of highly characterized individuals with longitudinal cognitive,
imaging and lifestyle data and biofluid collections, to aid in the development of interventions to delay onset, prevent or treat
AD. Harmonization with similar large longitudinal cohort studies is underway to further these aims.
Keywords: A-amyloid imaging, Alzheimer’s disease, biomarkers, cognition, cohort study, lifestyle, mild cognitive impair-
ment, observational longitudinal, preclinical Alzheimer’s disease, prodromal Alzheimer’s disease
INTRODUCTION
The Australian Imaging, Biomarkers and Lifestyle
(AIBL) Study assembled and assessed an Inception
cohort of 1,112 individuals from late 2006 to mid-
2008 with the intention of conducting re-assessments
every 18 months to determine the extent to which
their baseline cognitive profile, demographic factors,
A-amyloid brain load, blood and cerebrospinal fluid
(CSF) biomarkers, genetic and lifestyle factors could
predict their future cognitive function and clinical sta-
tus with respect to the development of Alzheimer’s
disease (AD) [1, 2]. The evolution of the Inception
cohort at baseline, 18, 36, 54, 72, 90, 108, and 126
months follow-up, was enriched with recruitment of
1,247 new participants to compensate for attrition
(Enrichment cohort), yielding the current database of
2,359 participants with 8,592 person-contact years.
The AIBL Study grew out of the Melbourne Aging
Study, initiated by Currie et al. in the 1990s [3–6].
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In the mid-2000s, the Commonwealth Scientific and
Industrial Research Organisation (CSIRO) success-
fully defended its patents concerning the use of fast
wireless local area network (WLAN) technology,
developed within its radio astronomy program. At the
time WLAN was being used by just about every Wi-
Fi-enabled laptop computer in the world. The ensuing
multi-million-dollar settlements with many compa-
nies (including Apple, Microsoft, HP, Dell, Nintendo,
and Netgear) were transferred into CSIRO’s Science
and Industry Endowment Fund (SIEF). This gave
Richard Head, then Chief of the CSIRO Division of
Human Nutrition, the opportunity to initiate and fund
a consortium to develop AIBL with a strong empha-
sis on cognitively normal (CN) individuals in their
70s and application of the then-emerging technology
of A-amyloid positron emission tomography (PET)
imaging.
Individuals with AD, mild cognitive impairment
(MCI), and those classified as CN were enrolled into
the Study in order to address the following aims: 1)
To improve understanding of the pathogenesis and
diagnosis of AD using psychometric, neuroimaging
and biomarker techniques, with a focus on early
diagnosis; 2) To examine lifestyle and diet factors
that may be involved in the pathogenesis of AD.
Here, we review the accomplishments of this 15-year-
long observational longitudinal cohort Study towards
addressing these aims, and more.
MATERIALS AND METHODS
Ethics approval
The AIBL study, including the follow-up proto-
col and subsequent amendments and revisions to the
protocol, was approved by the institutional human
research ethics committees of Austin Health, St Vin-
cent’s Health, Hollywood Private Hospital and
Edith Cowan University. All volunteers gave written
informed consent before participating in study assess-
ments, and the study was conducted in accordance
with the Helsinki Declaration of 1975.
Subjects
AIBL is a two-site study: Melbourne, Victoria
(60%) and Perth, Western Australia (40%). Initially
1,112 individuals were recruited at baseline [1] and
reassessed at 18 [2], 36, 54, 72, 90, 108, and 126
months (Inception cohort).
At baseline, subjects were classified as AD demen-
tia (n = 211), MCI (n = 133), and CN (n = 768). The
major exclusion criteria were age < 60 years, a his-
tory of non-AD dementia, schizophrenia, bipolar
disorder, current depression with a short Geriatric
Depression Scale score above 5/15 (for CN individu-
als), Parkinson’s disease, symptomatic stroke, current
uncontrolled or life threatening medical illness, diag-
nosed obstructive sleep apnea (OSA), past head injury
with over one hour of post-traumatic amnesia, or alco-
hol use above two standard drinks per day for women
or four per day for men.
Over the duration of this study, the Inception cohort
was enriched with an additional 1,247 subjects (719
CN, 282 MCI, 230 AD, and 18 with dementia other
than AD or cognitive impairment not suspected to be
due to AD; Enrichment cohort) both to compensate
for cohort attrition and to address new research ques-
tions. In 2018, the exclusion criterion for diagnosed
OSA was amended to exclude only those who were
not treated with continuous positive airway pressure
ventilation.
All cognitive and clinical data were considered by
a review panel, prior to participants being allocated
into one of five diagnostic groups: AD dementia by
NINCDS-ADRDA criteria, MCI by Winblad et al. [7]
and Petersen et al. [8] criteria, CN subjective memory
complainers (SMC), CN non-memory complainers
(NMC), and other (dementia other than AD or cog-
nitive impairment not suspected to be due to AD),
details of which are outlined below. SMC status was
determined by the subject’s ‘yes’ or ‘no’ response to
the single question “Do you have difficulty with your
memory?”.
Assessments took place at three locations in Mel-
bourne and at two locations in Perth, depending
on whether the participants were to undergo brain
imaging and where they lived. Some participants
(especially some with AD dementia), were assessed
by AIBL staff at home. All assessments were con-
ducted in the morning, after an overnight fast. Weight,
height, abdominal girth, sitting blood pressure and
pulse were measured, followed by the drawing of
80 mL of blood. Participants were then provided with
breakfast, before undergoing cognitive and mood
assessments, as described below.
Cognitive and mood assessments
Cognitive and mood assessments were performed
by trained staff, most of whom were qualified neu-
ropsychologists, and all of whom had undergone
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extensive training in the assessment techniques. Ass-
essors were blind to the A-amyloid scan status
when they undertook reviews. The length of a typical
assessment was around two hours. A more compre-
hensive account of the mood assessments, cognitive
battery and the rationale behind the selection of indi-
vidual items has been detailed previously [1]. Briefly,
the full assessment battery comprised the Mini-
Mental State Examination (MMSE) [9], California
Verbal Learning Test – Second edition (CVLT-II)
[10], Logical Memory I and II (WMS; Story 1 only)
[11], D-KEFS verbal fluency [12], 30-item Boston
Naming Test (BNT) [13], Wechsler Test of Adult
Reading (WTAR) [14] (the WTAR was not performed
at the 72 month follow-up), Digit Span and Digit
Symbol-Coding subtests of the Wechsler Adult Intel-
ligence Scale – Third edition (WAIS–III) [15], the
Stroop task (Victoria version) [16], and the Rey Com-
plex Figure Test (RCFT) [17]. As detailed in Table 1,
individual test scores were used to construct cog-
nitive domain composite scores for episodic recall
memory, recognition memory, executive function,
language, attention and processing speed, as well as
a composite referred to as the AIBL PACC (Preclin-
ical Alzheimer Cognitive Composite). Participants
also completed the computerized Cogstate battery
(www.cogstate.com), and for each Cogstate test the
speed (reaction time in milliseconds) and accuracy
(number of correct responses given) of performance
was recorded. A Cogstate Continuous Paired Asso-
ciate Learning Task was also included to assess visual
paired associate learning and for this the accuracy of
performance was calculated by totaling the number
of errors made in each round of the task.
Both the 15-item version of the Geriatric Depres-
sion Scale (GDS-15) [18] and the Hospital Anxiety
and Depression Scale (HADS) [19, 20] were admin-
istered at all visits. For participants with a diagnosis
of AD dementia, MCI, and for some CN partici-
pants where decline was suspected, an informant was
asked to provide additional information about the
functional performance of the research participant,
and to complete the 16-item version of the Informant
Questionnaire on Cognitive Decline (IQCODE) [21].
Dementia severity was rated for all participants
using the Clinical Dementia Rating scale (CDR) [22],
on the basis of information obtained from cogni-
tive testing, direct questioning of the participant, and
information from an informant and/or from the par-
ticipant’s treating clinician (for those diagnosed with
AD or MCI). The total CDR rating (range 0–3) and
the CDR ‘sum of boxes’ score (range 0–18) were
generated for each participant for each visit. The CDR
rating for each participant was also reviewed in detail
by an experienced CDR rater and clinician (DA) to
ensure consistency and accuracy of classifications.
As detailed above, the AIBL neuropsychologi-
cal battery is extensive, and multiple publications
have focused on development and validation of com-
posite scores to expedite assessment and clinical
classification, and to provide prognostic information
(e.g., [23–26]). However, given that AIBL partici-
pants range from CN to dementia, such composites
have never been proposed as a substitute for com-
prehensive assessment, but have been posited as dif-
ferentially sensitive at specific disease stages, and of
selective use in development of clinical trial designs,
for example, when participants from a narrower
Table 1
Cognitive domain composite score constituents
Cognitive domain composite Tests
Episodic recall memory CVLT-II Long Delay Free Recall
Logical Memory 2
Rey Complex Figure Long Delay Free Recall
Recognition memory CVLT-II ‘d prime’
Rey Complex Figure recognition total correct
Executive function Letter Fluency
Category switching total correct
Language BNT
Category Fluency




CVLT-II Long Delay Free Recall
Logical Memory 2
AIBL PACC, Australian Imaging, Biomarkers and Lifestyle Study Preclinical Alzheimer Cogni-
tive Composite; BNT, Boston Naming Test; CVLT-II, California Verbal Learning Test – Second
edition; MMSE, Mini-Mental State Examination.
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clinical spectrum are targeted (see Cognition section
of the Results for more information).
Clinical review and the diagnosis of AD
dementia or MCI
Monthly clinical review panel meetings were con-
ducted to discuss the diagnostic classification for all
potential AD or MCI participants. This included indi-
viduals with a probable baseline diagnosis of AD
or MCI, and those initially classed as CN whose
diagnostic status required further consideration. This
latter group included participants who demonstrated
any of the following: MMSE score < 28/30, failure
on the Logical Memory test (as per Alzheimer’s
Disease Neuroimaging Initiative (ADNI) criteria),
other evidence of possibly significant cognitive dif-
ficulty on neuropsychological testing, a CDR score
of 0.5 or greater, medical history suggestive of
the presence of illnesses likely to impair cognitive
function, informant or personal history suggestive
of impaired cognitive function, or consumption of
medications or other substances that could affect
cognition. A consensus diagnosis was assigned for
each such participant, using internationally agreed
diagnostic criteria according to both DSM-IV (Amer-
ican Psychiatric Association, 1994) and ICD-10
(World Health Organization, 1992). Where appro-
priate, ICD-10 dementia severity rating (WHO,
1992), NINCDS-ADRDA AD diagnosis (probable
or possible) and MCI classifications (amnestic/non-
amnestic, single/multi-domain) were applied.
MCI diagnoses were made according to a protocol
based on the criteria of Winblad et al. [7] which are
informed by the criteria of Petersen et al. [8]. Consis-
tent with Winblad criteria, all participants classified
with MCI had either personally, or through an infor-
mant, reported memory difficulties. Participants with
a baseline clinical diagnosis of MCI were required
to demonstrate a score 1.5 SD or more below the
age-adjusted mean on at least one neuropsychologi-
cal test applied at the time of the AIBL reassessment
in order to be retained in the MCI category. Indi-
viduals who were classed as CN at baseline had to
fulfil the more stringent criterion of impairment on
two or more cognitive tests at a level at least 1.5 SD
below the age-adjusted mean, in addition to having
reported memory difficulties, to be classified as MCI
at follow-up. The greater stringency applied to assign-
ing individuals presenting as CN to the MCI category
at follow-up was decided upon after extensive dis-
cussion, is justified by the acknowledged mutability
of MCI diagnoses, and replicates our practice when
diagnosing MCI at baseline. Individuals with MCI
were then characterized as being of the amnestic
or non-amnestic type, and also whether impairment
was single- or multi-domain, based on the profile of
impairment in the AIBL battery of neuropsycho-
logical tests. All participants classified with MCI
presented with intact activities of daily living and
exhibited no clear evidence of significant impairment
in their social or occupational functioning.
The clinical review panel comprised old age psy-
chiatrists, a neurologist, a geriatrician, and neu-
ropsychologists. A quorum was formed by three
members including at least one medically qualified
and at least one neuropsychologist member. The
panel conferred monthly by telephone conference,
and all meetings were attended by five or more panel
members. Diagnoses were made blind to the results
of AIBL neuroimaging data and apolipoprotein E
(APOE) genotype but were sometimes informed by
(non-A-amyloid) imaging conducted for indepen-
dent clinical reasons. Summary neuropsychological
data were available to the diagnostic panel.
Medical history and medication use
At baseline, participants (or their carer if the sub-
ject was cognitively impaired) completed a detailed
questionnaire regarding personal medical history,
medication use and smoking, and questions about
current and past alcohol and illicit drug use: this
information was reviewed and updated as needed at
follow-up assessments.
Brain imaging
At baseline, neuroimaging using magnetic reso-
nance imaging (MRI) and PiB-PET was performed
in 288 Inception cohort participants (178 CN, 57
MCI, and 53 mild AD); these findings have been
reported in detail elsewhere [27]. At subsequent
timepoints, additional Inception cohort participa-
nts underwent A-amyloid imaging using PiB,
NAV4694, flutemetamol, florbetapir, or florbetaben.
All Enrichment cohort participants were invited to
undergo brain imaging from baseline onwards. Indi-
viduals who had been imaged were invited to return
for further scans at 18-month intervals, so the rate of
A-amyloid accumulation and brain atrophy could
be determined. Tau-PET neuroimaging commenced
in 2013, using the AV1451 and MK6240 tracers.
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MRI scans were mainly acquired at three different
scanning centers, two in Melbourne using a Siemens
3T Trio (41% of scans) and a Siemens 3T Skyra (25%)
scanner, and one in Perth using a Siemens 3T Verio
(16%) and a Siemens 1.5T Avanto (13%) scanner.
The scans include a 3D MPRAGE (Magnetization
Prepared Rapid Acquisition Gradient Echo) image
(voxel size 1.2×1×1 mm3, repetition time/ echo
time = 2300/ 2.98, flip angle = 9◦). A 3D T2-weighted
FLuid Attenuation Inversion Recovery (FLAIR)
sequence was included in the image acquisition pro-
tocol, which was acquired using two different sets
of parameters: 1) in-plane resolution 0.98×0.98 mm,
slice thickness 0.9 mm, repetition time/ echo time/
inversion time =6000/ 420/ 2100, flip angle = 120◦,
field-of-view 240×256, and 176 slices; 2) in-plane
resolution 0.5 × 0.5 mm with in-plane interpolation
(factor of 2) enabled, slice thickness 1.0 mm, repe-
tition time/ echo time/ inversion time = 5000/ 355/
1800, flip angle = 120◦, field-of-view 256 × 256, and
160 slices. Gradient Recalled Echo (GRE) images
used for SWI (Susceptibility-Weighted Imaging) and
QSM (Quantitative Susceptibility Mapping) were
acquired with 0.93 × 0.93 mm in-plane resolution
and 1.75 mm slice thickness, repetition time/ echo
time = 27/ 20 ms, flip angle = 20◦, and field-of-view
240 × 256, for 80 slices [28].
Blood samples
Fasting blood samples (80 mL) were collected and
processed as described previously [1] for the purpose
of routine clinical pathology testing, and biobank-
ing. For biobanking, samples were processed to yield
whole blood, serum, plasma containing ethylene-
diaminetetraacetic acid (EDTA), plasma containing
lithium heparin, white blood cells, red blood cells,
and platelets. The EDTA collection tubes and wash-
ing buffers contained pre-added prostaglandin E1
at a final concentration of 33 ng/mL to prevent
platelet activation. Blood fractions were aliquoted
into volumes ranging from 100 L to 1 mL in screw-
cap 2D barcoded polypropylene Nunc Cryotubes
(NUN374088; Nalge Nunc International, Rochester,
NY, USA). Samples were snap-frozen, prior to being
transferred to a liquid nitrogen facility for long-term
storage.
Routine clinical pathology tests (full blood exa-
mination, urea, electrolytes, creatinine, glucose,
calcium, iron studies, total cholesterol and choles-
terol subfractions, homocysteine, liver and thyroid
function tests, vitamin B12, folate, ceruloplasmin,
hormone levels) ceased after the 72-month follow-up
due to financial constraints, and a diminishing utility
of these results for research purposes. Basic clinical
pathology test results were available to the diagnostic
review panel if needed, and results outside the nor-
mal range were flagged for immediate attention and
reporting to the participant’s regular doctor.
Cerebrospinal fluid samples
In a subgroup of participants CSF was collected
in the morning by routine lumbar puncture after
overnight fasting, employing a protocol similar to
that recommended by the Alzheimer’s Biomarkers
Standardization Initiative [29]. CSF was directly
collected into polypropylene tubes (Greneir Bio-
One188271), and immediately placed on wet ice. The
tubes were gently mixed by repeated inversion and
CSF was centrifuged within 45 min (2000 × g, 4◦C,
for 10 min). The supernatant was removed into a new
polypropylene tube and gently inverted three times
to avoid possible gradient effects. Samples were then
aliquoted into screwcap 2D barcoded polypropylene
Nunc Cryotubes (NUN374088) and frozen within 1 h
of lumbar puncture, prior to being transferred to a
liquid nitrogen facility for long-term storage. The
remaining cell pellet was resuspended in 100 L of
CSF, and also stored in Nunc Cryotubes in liquid
nitrogen. Polypropylene tubes were used for the sam-
pling and storage to minimize reported plastic surface
effects [29].
CSF was tested routinely using the INNOTEST®
kit assay (Innogenetics, now Fujirebio Europe N.V.,
Ghent, Belgium) for Abeta 1–42 (A42), total tau
(tTau) and phospho-tau 181 (pTau181), with thresh-
olds for CSF biomarker positivity determined using a
rank order approach (0.10 fractile for A42 and 0.90
fractile for tTau and pTau181) against a Pittsburgh
Compound B (PiB) Standardized Uptake Value Ratio
(SUVR) of 1.4 (or equivalent in other tracers) [30].
Participants with three or more collections of CSF
have also been analyzed using automated Elecsys®
assays (Roche Diagnostics) for A42, A1–40, tTau,
and pTau181 [31].
Lifestyle measures
All participants were asked to complete the Inter-
national Physical Activity Questionnaire (IPAQ)
[32], the Cancer Council of Victoria Food Fre-
quency Questionnaire (CCVFFQ) [33], and the
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Pittsburgh Sleep Quality Index (PSQI) [34]. The
IPAQ collects data on self-reported physical activ-
ity undertaken during the previous seven days, the
CCVFFQ assesses usual dietary intake over the pre-
ceding 12 months, and the PSQI captures information
in relation to the previous month’s sleep habits. IPAQ
data were collected at each timepoint, CCVFFQ data
were collected at alternating timepoints; i.e., base-
line, 36-months, 72-months, etc. PSQI data were
collected at each timepoint, from 72-months onwards
for the Inception cohort, and from baseline onwards
for Enrichment cohort participants. Objective mea-
sures of physical activity and body composition were
also obtained from a subset of the cohort using Acti-
Graph Uni-axial Accelerometers and Dual Energy
X-Ray Absorptiometry (DXA) scans respectively.
Genetic data
QIAamp DNA Blood Maxi Kits (Qiagen, Hilden,
Germany) were used for the extraction of DNA from
5 mL of whole blood, as per the manufacturer’s ins-
tructions. Neat DNA was aliquoted and stored at
–80◦C for downstream analyses.
APOE and brain-derived neurotrophic factor (BD
NF; Val66Met) genotypes were determined by Taq
Man® genotyping assays (Life Technologies, USA).
Specifically, for APOE rs7412 (Assay ID: C
904973 10) and rs429358 (Assay ID: C 308
4793 20) and for BDNF, rs6265 (Assay ID: C
11592758 10). These were carried out on a Quant-
StudioTM 12K Flex Real-Time-PCR system (Applied
Biosystems™, USA), as per the manufacturer’s
instructions.
Genome-wide single nucleotide polymorphism
(SNP) array data were derived on 1357 AIBL par-
ticipants. Genome-wide analysis was performed on
976,713 SNPs (including 273,000 exome variants
and an additional 13,000 custom content SNPs) on
the OmniExpressHumanExome + BeadChip (Illum-
ina, USA). Genetic markers were mapped to human
genome reference hg19 and standard quality control
(QC) was undertaken at marker and sample levels
in PLINK [35]. Markers that were duplicated, with
< 95% call rate, and/or unmappable were removed,
and samples with call rate < 98%, mismatch gen-
der and/or high heterozygosity rate were removed.
Post-QC, 948,720 markers and 1315 samples were in-
cluded in the pre-imputed AIBLgene (ver1.0) data-
set. This dataset was further imputed to the 1000
Genomes Project Phase 3 [36] using the Michi-
gan Imputation Server [37]. At the time of
manuscript submission, the remaining AIBL Enri-
chment cohort and additional samples, for QC and
cross-platform validation, were undergoing gen-
omewide SNP array processing using the Axiom
Precision Medicine Diversity Array (Applied Bio-
systems™).
Whole exome sequencing was undertaken on 1 g
of DNA, extracted as described above, from 500
AIBL participants. Exonic sequence enrichment was
performed by hybridisation using the SureSelect
Human All Exon V5 (51 Mb) Kit (Agilent Tech-
nologies, USA). Resulting sequence libraries were
sequenced on the Illumina HiSeq2500 using 100 bp
paired-end read chemistry with a minimum of 36x
mapped coverage. Four hundred and ninety-seven
samples progressed from raw sequencing through to
sequence alignment. The Burrows-Wheeler Aligner
(BWA) was used for the alignment of raw sequence
data to the human genome reference (build GRCh37,
1kG reference) [38], and the open-source Picard
Tools (available from: http://picard.sourceforge.net.)
was used for the removal of PCR/optical dupli-
cates. Realignment of data around indel positions and
recalibration of base quality scores was performed
using the Genome Analysis ToolKit 3.3 (GATK3.3)
[39]. The GATK HaploTypeCaller was used for
per-sample genotyping according to GATK Best
Practices. Finally, the annotation of per-sample vari-
ants was performed using Ensembl’s Variant Effect
Predictor (VEP) [40].
Genome-wide methylation analysis was per-
formed on 726 AIBL participants at a single timepoint
(AIBL Inception participants at 18-month follow-up:
318 CN, 34 MCI, and 123 AD; AIBL Enrichment
participants at baseline: 153 CN, 60 MCI, and 38
AD). Prior to bisulfite conversion, extracted DNA
was processed through Amicon® Ultra-0.5 Centrifu-
gal Filters (Merck, USA), following manufacturer’s
instructions, to remove any guanidine isothiocyanate
introduced during the extraction process. Cleaned
DNA was first standardized to 500 ng using a method
previously described [41] before undergoing bisul-
phite conversion using the Illumina recommended
protocol for the EZ DNA Methylation Kits (ZYMO
Research, USA). Bisulfite converted DNA samples
were hybridized to the eight sample HumanMethy-
lationEPIC BeadChip Array using the Infinium HD
Methylation protocol (Illumina, USA). The Meffil
R package [42] was used for data QC and normal-
ization as previously described [41], with technical
variation removed by functional normalization [43].
At the time of manuscript submission, a subset of
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400 of the above 726 participants also have sam-
ples, from two additional timepoints, undergoing the
same workflow. This will generate a 400-sample lon-
gitudinal genome-wide peripheral DNA methylation
dataset.
RESULTS
Major achievements (including publications and
citations)
AIBL data have confirmed the diagnostic and prog-
nostic power of A-amyloid imaging [44], permitted
direct calculation of the very slow accumulation rate
of AD-related pathologic change [45, 46], shown
the best measures for tracking very early cognitive
decline [47, 48], and revealed a wide window for
early intervention [45]. These early estimates of A-
amyloid-related cognitive change provided a basis
for estimation of power for therapeutic trials in pre-
symptomatic AD [49]. Prospective AIBL data have
also shown the powerful interaction of several genes,
either independently or combined in genetic profiles
or polygenic risk scores (PRS), on cognitive decline
in preclinical and prodromal stages of AD [45, 47,
50–52] suggesting that the genetic architecture of AD
progression may differ from that of risk. With addi-
tional genetic data and detailed lifestyle analysis now
emerging from the cohort, AIBL is revealing further
important genetic and lifestyle interactions (e.g., [53,
54]) that will guide future tailored early intervention
and prevention trials and place AIBL at the forefront
of the emerging field of lifestyle genomics (LGx) in
AD.
Table 2 lists the 10 highest cited papers produced
using AIBL data. Most relate to the nosology of AD,
particularly in its preclinical stages, and the utility and
applicability of PET as a biomarker of A-amyloid
and tau accumulation. Supplementary Table 1 lists
each of the 341 AIBL-related manuscripts either
published in peer reviewed journals or accepted for
publication as of 31 December 2020. The highest per-
centage (33%) focus on issues related to the nature
and magnitude of cognitive changes in preclinical,
prodromal and clinical AD, 28% relate to biomark-
ers (including genetics), 28% to neuroimaging, and
11% to lifestyle (Fig. 1).
Cohort reassessment
Table 3 details characteristics of the cohort at
baseline, while Fig. 2 shows the total number of
participants from both the Inception and Enrichment
cohorts assessed at baseline and reassessed at 18, 36,
54, 72, 90, 108, and 126 months (the baseline and
18 month data for the Inception cohort have been
published previously [1, 2]) and both the initial diag-
nostic category to which each volunteer was assigned
at baseline and the diagnostic category after each
reassessment and clinical review. For ease of inter-
pretation the NMC and SMC categories have been
combined into a single CN group in this complex
figure, as there was no difference in the rate of attri-
tion, deaths or change in cognitive status between
these two groups over time, and there was con-
siderable movement of participants between these
two categories across timepoints. Collectively, these
assessments equate to 8,592 person-years of investi-
gation (Table 4).
Of the 1,112 participants in the Inception cohort,
follow-up data were collected for 89.6% at 18
months, 80.6% at 36 months, 73.5% at 54 months,
64.5% at 72 months, 58.0% at 90 months, 52.6%
at 108 months, and 32.6% at 126 months. Of note,
due to financial constraints, participants willing to
undergo brain scans were prioritized for assessment
at 126 months; hence the significant reduction in the
number of assessments at this timepoint.
Of the 133 Inception cohort baseline MCI partic-
ipants, 56 (42%) developed AD by the 126-month
timepoint, whilst three developed vascular dementia,
one developed frontotemporal dementia (FTD) and
one developed Parkinson’s disease dementia. Three
of the original MCI subjects were classified as MCI
throughout the study, whilst eight MCI subjects were
reclassified as CN at least once in the study follow-
up sequence, with three of these reverting to MCI
by their last follow-up visit and one transitioning to
AD.
Thirty of 768 Inception cohort participants (3.9%)
who were CN at baseline developed AD by 126
months and 19 of these were classed as having MCI
on at least one follow-up visit prior to the develop-
ment of AD. Two CN subjects developed vascular
dementia by the 126-month follow-up, one devel-
oped progressive supranuclear palsy and one FTD.
Fifty-eight subjects (7.6%) who were CN at baseline
developed MCI by 126 months but had not progressed
to exhibit dementia, and a further twenty-one subjects
(2.7%) developed MCI but reverted to CN status. Two
hundred and ninety (37.8%) were classed as CN at
every follow-up they attended.
Of the 441 individuals (Inception plus Enrichment
combined) classified as AD at baseline, by 54 months,
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Table 2
Top AIBL Study and AIBL investigator-co-authored papers, determined via combining Google
Scholar Citations, ISI, Altmetrics, and FWCI scores
Citation Impact Measures
Sperling RA, Aisen, PS, Beckett LA, Bennett DA, Craft S, Fa gan AM, Iwatsubo
T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E,
Stern Y, Yaffe K, Carrillo M, Thies B, Morrson-Bogorad M, Wagster MV,
Phelps CH (2011) Toward defining the preclinical stages of Alzheimer’s disease:
recommendations of the National Institute on Aging and the Alzheimer’s





Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K,
DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S,
Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert MO, Jicha GA,
Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe CC, Salloway S, Sarazin
M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y,
Scheltens P, Cummings JL (2014) Advancing research diagnostic criteria for





Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TF, Dickinson
KL, Maruff P, Darby D, Smith C, Woodward M, Merory J, Tochon-Danguy H,
O’Keefe G, Klunk WE, Mathis CA, Price JC, Masters CL, Villemagne VL






Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke
C, Macaulay SL, Martins RN, Maruff P, Ames D, Rowe CC, Masters CL (2013)
Amyloid  deposition, neurodegeneration and cognitive decline in sporadic





Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chételat G,
Dubois B, Dufouil C, Ellis KA, van der Flier WM, Glodzik L, van Harten AC,
de Leon MJ, McHugh P, Mielke MM, Molinuevo JL, Mosconi L, Osorio RS,
Perrotin A, Petersen RC, Rabin LA, Rami L, Reisberg B, Rentz DM, Sachdev
PS, dela Sayette V, Saykin AJ, Scheltens P, Shulman MB, Slavin MJ, Sperling
RA, Stewart R, Uspenskaya O, Vellas B, Visser PJ, Wagner M and the
Subjective Decline Initiative (SCD-I) Working Group (2014) A conceptual
framework for research on subjective cognitive decline in preclinical





Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J,
Tochon-Danguy H, Morandeau L, O’Keefe G, Price R, Raniga P, Robins P,
Acosta O, Lenzo N, Szoeke C, Salvado O, Head R, Martins R, Masters CL,
Ames D, Villemagne VL (2010) Amyloid imaging results from the Australian






Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, Mathis CA, Klunk
WE, Masters CL, Rowe CC (2007) β-amyloid imaging and memory in






Villemagne VL, Pike KE, Chételat G, Ellis KA, Mulligan R, Bourgeat P,
Ackermann U, Jones G, Szoeke C, Salvado O, Martins R, O’Keefe G, Mathis
CA, Klunk WE, Ames D, Masters CL, Rowe CC (2011) Longitudinal






Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P, Lautenschlager NT,
Lenzo N, Martins RN, Maruff P, Masters CL, Milner A, Pike K, Rowe CC,
Savage G, Szoeke C, Taddei K, Villemagne VL, Woodward M, Ames D and the
AIBL Research Group (2009) The Australian Imaging, Biomarkers and
Lifestyle (AIBL) study of ageing: methodology and baseline characteristics of






Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC (2015) Tau imaging:





FWCI, Field-Weighted Citation Impact; ISI, International Scientific Indexing.
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Fig. 1. AIBL-related publications by calendar year (A) and by primary research focus (B). At the time of writing, more than 340 AIBL-related
manuscripts have been published since study commencement. ∗Biomarker publications include those related to fluid biomarkers (blood,
cerebrospinal fluid), buccal cells and genetics.
Table 3
Characteristics of the cohort at baseline
CN MCI AD Other
N 1487 413 441 18
Age, y 71.1 73.8 75.1 68.5
Female, % 57.2 48.7 55.9 27.8
APOE 4 carrier, % 28.1 53.6 64.5 25.0
Education, y 13.1 12.2 12.1 13.2
MMSE 28.6 26.0 20.5 22.2
CDR Global 0.03 0.50 0.91 0.78
Data are represented as means unless otherwise stated. AD,
Alzheimer’s disease; APOE, Apolipoprotein E, CDR, Clinical
Dementia Rating; CN, Cognitively Normal; MCI, Mild Cogni-
tive Impairment; MMSE, Mini-Mental State Examination; Other,
Dementia other than AD or cognitive impairment not suspected to




CN MCI AD Other Total
Years 6,477 796.5 1,234.5 84 8,592
AD, Alzheimer’s disease; CN, cognitively normal; MCI, mild cog-
nitive impairment; Other, dementia other than AD or cognitive
impairment not suspected to be due to AD.
four had transitioned to dementia other than AD or
cognitive impairment not suspected to be due to AD
(Other), and three to MCI. No other transitions were
observed for those with a baseline clinical classifica-
tion of AD.
The Enrichment cohort has now reached 1,247
individuals, with 622 individuals having undergone
at least one follow-up assessment included in this
report. The Enrichment cohort initially focused on
recruiting CN participants to investigate the preclin-
ical stages of AD, however, from 2016 onwards the
Enrichment cohort has increased participant recruit-
ment via referral from memory specialists with a
focus on MCI and early AD; these more recent
recruits subsequently drop out at a higher rate to
participate in therapy trials. Overall, the Enrichment
cohort has maintained the percentage of AD partic-
ipants at 18% and has seen the percentage of MCI
participants increase from 12% (Inception) to 22%
(Enrichment); greatly increasing the cross-sectional
dataset of PET-A-amyloid imaging and replenish-
ing biobank stores.
Unsurprisingly, for both the Inception and Enrich-
ment cohorts combined, the number of deaths at any
timepoint was greatest in those classified with demen-
tia due to AD, and those with AD were most likely
to drop out of the study. By 126 months only 5
of the 211 Inception cohort AD subjects were still
engaged with the study: 97 were known to have died
and 109 had withdrawn and their current status was
unknown.
Overall, for Inception and Enrichment cohorts
combined, attrition was 1203 persons (of 2359, or
51%). Of these, 216 were known to have died and
987 failed to return. Of those who failed to return,
290 (29%) offered no specific reason, 133 (14%) were
uninterested, 107 (11%) cited concomitant physical
or medical illness, 88 (9%) found it too difficult
logistically or had moved away, 65 (7%) were too
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cognitively impaired, 43 (4%) found it psychologi-
cally distressing, 32 (3%) reported being too busy,
and 21 (2%) were unwilling to undergo PET neu-
roimaging or CSF collection. One hundred and eight
subjects (11%) were withdrawn for other reasons
(e.g., they entered a therapy trial, data collection was
incomplete) and 100 (10%) were unable to be con-
tacted.
Cognition
As impairment in cognition is the cornerstone man-
ifestation of AD in both the preclinical and clinical
stages, studies arising from the AIBL cohort con-
firmed the nature and magnitude of cognitive impair-
ment in adults with MCI and dementia in this well
characterized sample. These studies were the first
Fig. 2. Consort diagram illustrating the study cohort composition from baseline to 126 months. The numbers include Inception and Enrichment
cohort participants. Solid black arrows indicate study participants remaining within a clinical classification, across timepoints. Broken black
arrows indicate the transition of study participants from one clinical classification to another, across timepoints. Tabulated information details
loss to follow up of participants due to death or study withdrawal, or those who missed the previous assessment but returned for the current
assessment timepoint. AD, Alzheimer’s disease; CN, cognitively normal; MCI, mild cognitive impairment; Other, dementia other than AD
or cognitive impairment not suspected to be due to AD.
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to use prospective analyses to identify how abnor-
mally high levels of A-amyloid (A+), detected
via PET were associated with a subtle but relentless
decline in memory and other aspects of higher cog-
nition in CN older adults; even though these adults
showed no change in their clinical status over the
same time period [48, 55, 56]. From the opposite
perspective we were also the first to demonstrate
that in CN older adults, A+status detected using a
plasma A composite biomarker successfully pre-
dicted decline in memory and executive function,
and that the magnitude of this decline was equiva-
lent to that observed when A+status was classified
using PET neuroimaging [57]. Over the course of 126
months, it also became clear that the CN older adults
who had met the rigorous AIBL inclusion/exclusion
criteria but who had normal levels of brain A-
amyloid (A-), showed no decline in cognition over
the same time-period, challenging the notion of age-
related cognitive decline [58, 59].
The AIBL study was also the first to make use of
computerized assessments of cognition in their exper-
imental designs [60]. Data from the Cogstate Brief
Battery (CBB), applied repeatedly in the AIBL study,
showed that A-amyloid-related cognitive decline
could be detected on the basis of relatively brief
assessments of visual learning and working mem-
ory in both preclinical and prodromal AD, and that
this decline was associated strongly with loss of
volume in medial temporal lobe brain regions [25,
61]. Furthermore, consistent with our observations
using conventional neuropsychological tests, decline
in performance on the CBB measures of learn-
ing and working memory was increased further in
A + individuals who also carried at least one APOE
4 allele [62]. The brevity of the CBB resulted in
its use in an AIBL sub-study that sought to deter-
mine whether sensitivity to AD-related change was
increased with reassessments conducted more fre-
quently than the 18-month time period used for
AIBL. Results from this ‘Rate Of Change Sub-study’
(AIBL-ROCS), confirmed that increased numbers of
reassessments (i.e., > 8) improved sensitivity to A-
amyloid-related cognitive change in both preclinical
and prodromal AD [63]. These data provided the
foundation for the use of the CBB in other studies
of AD genesis (e.g., the Mayo study of Health and
Aging [64]) and in clinical trials designed to treat AD
by clearing A-amyloid prior to the development of
cognitive impairment (e.g., [65, 66]).
As the AIBL sample and the number of reassess-
ments increased, we identified that known genetic
risk factors for AD, such as the APOE 4 allele
and variation in the BDNF Val66Met polymorphism,
substantially influenced the course of cognitive
decline, brain volume loss and clinical disease
progression [47, 67]. For example, sophisticated
modelling showed that the rate of decline in memory
associated with A+status increased with age, and
this increase was greater in APOE 4 carriers [67].
These studies also showed that decline in cognition
through the preclinical and prodromal stages of AD
was associated more strongly with changes in brain
volume loss, than with increasing A-amyloid lev-
els [61]. As the duration of follow-up increased past
72, to 90 months, which meant that the number of
re-assessments conducted also increased, the presen-
tation of A-amyloid-related cognitive dysfunction
changed. Trajectories of memory performance in pre-
clinical AD became flat (i.e., with slopes of zero),
while performance in matched A- adults improved
[68]. This failure to benefit from experience observed
in preclinical AD led to the development of exper-
imental models which have now shown that the
earliest and most severe cognitive impairment in pre-
clinical AD manifests as a reduction in learning, as
opposed to impairment in memory [69]. Moreover,
with the knowledge that it is possible to identify
cognitive dysfunction in A- CN adults, we have
sought to challenge our cognitive models further by
recruiting and assessing middle-aged adults who are
genetically at-risk of developing AD (i.e., APOE 4
carriers). This has led to the development of the
Healthy Brain Project, which is an online prospec-
tive cohort study designed to survey and test a large
number of individuals with a family history of demen-
tia [70]. Initial studies have already demonstrated
that cognitive impairment in middle-aged APOE 4
homozygotes can be readily detected using online
tests of learning.
PET- Aβ-amyloid/tau
The number of PET-A-amyloid scans conducted
by calendar year, by clinical classification and
PET-A status (-ve/+ve), as well as by clinical clas-
sification progression group (CN to MCI to AD) is
shown in Tables 5, 6, and 7 respectively. To date 1685
participants have undergone at least one A-amyloid
brain scan with 518 individuals undergoing three or
more scans.
The application of A-amyloid PET imaging from
study commencement has enabled AIBL researchers
to make seminal contributions to understanding
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Table 5
Number of PET-A-amyloid scans conducted each calendar year
Collection∗ 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 Total
T0 4 109 175 0 17 32 135 315 105 207 257 201 90 38 1,685
T1 0 0 20 171 33 2 2 88 194 119 59 79 135 39 941
T2 0 0 0 1 47 119 11 2 2 36 97 99 76 28 518
T3 0 0 0 0 0 12 90 32 7 1 2 10 50 9 213
T4 0 0 0 0 0 0 0 41 53 14 6 0 0 1 115
T5 0 0 0 0 0 0 0 0 11 52 17 12 2 1 95
T6 0 0 0 0 0 0 0 0 0 0 0 24 22 4 50
T7 0 0 0 0 0 0 0 0 0 0 0 0 6 0 6
Total 4 109 195 172 97 165 238 478 372 429 438 425 381 120 3,623
∗Positron Emission Tomography (PET)-A-amyloid collection is case-wise; i.e., T0 represents the first time a participant is imaged but may
not correspond to their baseline cognitive assessment, T1 represents the second time a participant is imaged but may not correspond to their
18 month follow-up cognitive assessment, etc. The following A-amyloid tracers were utilized: Pittsburgh Compound B (PiB), NAV4694,
flutemetamol, florbetapir, or florbetaben.
Table 6
Number of PET-A-amyloid scans conducted by clinical classification and PET-A status
PET-A-amyloid collection
Clinical classification T0 T1 T2 T3 T4 T5 T6 T7 Total
and PET-A status
CN -ve 773 533 282 119 62 51 30 3 1,853
CN +ve 305 168 121 52 24 24 14 3 711
MCI -ve 103 53 25 12 6 4 1 0 204
MCI +ve 225 66 31 9 8 4 2 0 345
AD -ve 26 8 5 0 0 1 0 0 40
AD +ve 231 95 44 15 9 5 3 0 402
Other -ve 13 5 1 3 3 3 0 0 28
Other +ve 4 5 4 1 1 1 0 0 16
Not classified∗ 5 8 5 2 2 2 0 0 24
Total 1685 941 518 213 115 95 50 6 3,623
∗Imaged but withdrawn from cognitive stream. ‘PET-A-amyloid collection’ is case-wise; i.e., T0 represents the first time a participant is
imaged but may not correspond to their baseline cognitive assessment, T1 represents the second time a participant is imaged but may not
correspond to their 18 month follow-up cognitive assessment, etc. The following A-amyloid tracers were utilized: Pittsburgh Compound
B (PiB), NAV4694, flutemetamol, florbetapir, or florbetaben. -ve, A-amyloid negative (≤ 20 Centiloids);+ve, A-amyloid positive (> 20
Centiloids); AD, Alzheimer’s disease; CN, cognitively normal; MCI, mild cognitive impairment; Other, dementia other than AD or cognitive
impairment not suspected to be due to AD; PET, positron emission tomography.
AD progression. We demonstrated that A-amyloid
likely accumulates for 30 years to reach the level typi-
cally present in mild AD dementia, and that abnormal
levels can conceivably be detected with PET 15–20
years before the onset of dementia [46, 71], iden-
tifying a wide window for prevention trials in the
asymptomatic and prodromal disease phases.
AIBL has also confirmed the role of A-amyloid
in conversion from MCI to AD. Over 3 years, conver-
sion risk in the cohort was associated most strongly
with a positive A-amyloid scan (odds ratio (OR)
15) with a positive predictive value of 84% [45].
The A-amyloid-PET scan likely becomes positive
15–20 years prior to mild dementia, a decade before
other imaging and cognitive tests become abnormal
[45].
The recent development of tau-PET scans and their
subsequent implementation in AIBL will likely yield
further important insights into the development of
AD. The number of tau-PET scans conducted by cal-
endar year and by clinical classification in AIBL is
depicted in Tables 8 and 9, respectively. To date 470
participants have undergone tau imaging, with 88 of
these individuals undergoing at least one follow-up
tau scan.
Magnetic resonance imaging
Nine hundred and fifty-four subjects have under-
gone structural MR imaging at least once (Table 10).
Structural MRI using T1W Magnetization Pre-
pared RApid Gradient Echo (MPRage) was used to
elucidate the relationship between atrophy and A-
amyloid both cross-sectionally [72, 73] and longitu-
dinally [45, 74]. An association between A-amyloid
deposition and atrophy in asymptomatic individuals
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Table 7
Number of PET-A scans conducted by clinical classification pro-
gression group, and PET-A status
PET-A status
Clinical -ve +ve Total Not
classification scanned scanned
CN 685 286 971 340
CN/MCI-CN 31 16 47 5
CN-MCI 24 45 69 31
MCI 70 148 218 61
CN-AD 3 22 25 12
MCI-AD 11 64 75 25
AD 25 219 244 195
Other 20 14 34 7
Total 869 814 1,683 676
Individuals scanned (-ve,+ve, and Total scanned columns) have
undergone at least one PET scan. Clinical classification groups
are defined as follows: CN, MCI, AD, Other = individuals
remain in these groups throughout study participation. CN/MCI-
CN = individuals move from the CN classification to MCI, then
back to CN during study participation. CN-MCI = progression
from CN to MCI clinical classification during study participation.
CN-AD = progression from CN to AD clinical classification dur-
ing study participation. MCI-AD = progression from MCI to AD
clinical classification during study participation. The clinical clas-
sification changes refer to the clinical visit history of a participant,
while the T0 PET scan can occur at any stage during the AIBL visit
history. For example, a participant could be listed as CN-MCI-AD,
but the T0 PET scan occurred at the MCI or the AD stage. The fol-
lowing A-amyloid tracers were utilized: Pittsburgh Compound
B (PiB), NAV4694, flutemetamol, florbetapir, or florbetaben. -ve,
A-amyloid negative (≤ 20 Centiloids); +ve, A-amyloid positive
(> 20 Centiloids); AD, Alzheimer’s disease; CN, cognitively nor-
mal; MCI, mild cognitive impairment; Other, ementia other than
AD or cognitive impairment not suspected to be due to AD; PET,
positron emission tomography.
was observed, as was little-to-no overlap between the
patterns of atrophy and that of A-amyloid depo-
sition. In other studies, atrophy was also related to
cognition (hippocampal volume; [25]) and physical
activity (hippocampal and temporal lobe volumes;
[75]), as well as to BDNF and KIBRA (KIdney and
BRAin expressed protein) polymorphisms [75–77].
In addition to structural sequences, the AIBL MR
protocol also includes FLuid-Attenuated Inversion
Recovery (FLAIR) imaging, used to assess white
matter lesions. These lesions were shown to be related
to cognitive decline, neurodegeneration and age, but
were not associated with rate of A-amyloid accu-
mulation [78, 79].
A subset of AIBL participants was imaged using
more advanced MRI sequences including Diffusion
Weighted Imaging (DWI), Arterial Spin Labelling
(ASL), and Susceptibility Weighted Imaging (SWI).
DWI was used to show a reduction of specific wh-
ite matter fibers in AD [80]. An increase in cerebral
blood flow, as measured using ASL, was observed
in preclinical AD subjects, and linked with an
increase in A-amyloid [81]. Higher risk of cerebral
microbleeds, as measured with SWI, was evident for
subjects with high A-amyloid burden [82]. More
recently, the SWI data were reconstructed to pro-
vide Quantitative Susceptibility Mapping (QSM) for
iron deposition measurement. These data showed that
QSM could predict A-related cognitive decline in a
mixed diagnostic group [28]. More work is required
to determine whether iron plays a role in enhancing
susceptibility to A-mediated neurodegeneration, or
Table 9
Number of PET-tau scans conducted by clinical classification
PET-tau collection
Clinical T0 T1 T2 T3 Total
classification
CN 292 62 17 4 375
MCI 97 16 0 0 113
AD 78 10 1 0 89
Other 3 0 0 0 3
Total 470 88 18 4 580
‘PET-tau collection’ is case-wise; i.e., T0 represents the first time
a participant is PET-tau imaged but may not correspond to their
baseline cognitive assessment, T1 represents the second time a
participant is PET-tau imaged but may not correspond to their 18
month follow-up cognitive assessment, etc. The following tau trac-
ers were utilized: AV1451 and MK6240. AD, Alzheimer’s disease;
CN, cognitively normal; MCI, mild cognitive impairment; Other,
dementia other than AD or cognitive impairment not suspected to
be due to AD; PET, positron emission tomography.
Table 8
Number of PET-tau scans conducted each calendar year
Collection∗ 2014 2015 2016 2017 2018 2019 Total
T0 15 50 32 9 134 230 470
T1 0 7 37 9 4 31 88
T2 0 10 8 18
T3 0 0 4 4
Total 15 57 69 18 148 273 580
∗Positron Emission Tomography (PET)-tau collection is case-wise; i.e., T0 represents the first time a participant is PET-tau imaged but may
not correspond to their baseline cognitive assessment, T1 represents the second time a participant is PET-tau imaged but may not correspond
to their 18-month follow-up cognitive assessment, etc. The following tau tracers were utilized: AV1451 and MK6240.
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Table 10
Number of MRI scans conducted by clinical classification and PET-A status
MRI collection
Clinical classification T0 T1 T2 T3 T4 T5 T6 T7
and PET-A status
CN -ve 442 370 193 104 102 47 12 17
CN +ve 228 94 54 31 38 16 2 9
MCI -ve 58 31 20 8 9 1 1 0
MCI +ve 105 36 16 7 12 1 1 0
AD -ve 12 4 4 0 0 1 0 0
AD +ve 103 62 24 19 9 5 1 1
Other -ve 3 3 2 4 3 0 1 0
Other +ve 3 3 2 0 1 1 0 0
Total 954 603 315 173 174 72 18 27
‘MRI collection’ is case-wise; i.e., T0 represents the first time a participant undergoes MRI but may not correspond to their baseline cognitive
assessment, T1 represents the second time a participant undergoes MRI but may not correspond to their 18-month follow-up cognitive
assessment, etc. The following A-amyloid tracers were utilized: Pittsburgh Compound B (PiB), NAV4694, flutemetamol, florbetapir,
or florbetaben. -ve, A-amyloid negative (≤ 20 Centiloids);+ve, A-amyloid positive (> 20 Centiloids); AD, Alzheimer’s disease; CN,
cognitively normal; MCI, mild cognitive impairment; MRI, magnetic resonance imaging; Other, dementia other than AD or cognitive
impairment not suspected to be due to AD; PET, positron emission tomography.
Table 11
Number of CSF collections by clinical classification progression group, and PET-A status
Latest PET-A
Result
Clinical -ve +ve Not Total N with ≥ 2 N with ≥ 3
classification scanned collections collections
CN 104 54 11 169 78 27
CN/MCI-CN 4 5 0 9 7 3
CN-MCI 2 4 1 7 5 1
MCI 9 14 3 26 5 0
CN-AD 0 2 0 2 2 0
MCI-AD 1 6 1 8 4 2
AD 1 30 3 34 6 0
Other 4 2 1 7 2 0
Total 125 117 20 262 109 33
Clinical classification groups are defined as follows: CN, MCI, AD, Other = individuals remain in these groups throughout study participation.
CN/MCI-CN = individuals move from the CN classification to MCI, then back to CN during study participation. CN-MCI = progression
from CN to MCI clinical classification during study participation. CN-AD = progression from CN to AD clinical classification during study
participation. MCI-AD = progression from MCI to AD clinical classification during study participation. The clinical classification changes
refer to the clinical visit history of a participant, while the T0 CSF collection can occur at any stage during the AIBL visit history. For example,
a participant could be listed as CN-MCI-AD, but the T0 CSF collection occurred at the MCI or the AD stage. The following A-amyloid
tracers were utilized to determine -ve/+ve status: Pittsburgh Compound B (PiB), NAV4694, flutemetamol, florbetapir, or florbetaben. -ve,
A-amyloid negative (≤ 20 Centiloids); +ve, A-amyloid positive (> 20 Centiloids); AD, Alzheimer’s disease; CN, cognitively normal;
CSF, cerebrospinal fluid; MCI, mild cognitive impairment; Other, dementia other than AD or cognitive impairment not suspected to be due
to AD; PET, positron emission tomography.
if iron deposition is instead a reflection of underlying
damage to the brain.
Blood biomarkers: plasma Aβ/tau, lipidomics
and metabolomics
Fasted blood samples have been collected at each
18-monthly participant visit, and 587,665 blood frac-
tion aliquots have been stored in liquid nitrogen.
This number includes over 100,000 serum aliquots,
200,000 EDTA plasma aliquots, 100,000 lithium hep-
arin plasma aliquots, 35,000 platelet aliquots, 40,000
aliquots of Ficoll-purified white blood cells (stored
in either dH2O or ‘RNA later’), and 90,000 aliquots
of red blood cells.
Since AIBL commenced in 2006, high on the list
of priorities has been the objective of developing a
robust blood test for AD. We first confirmed the pres-
ence of A dimers in plasma [83] and then explored
the utility of early A immunoassays [53, 75, 84–89].
These results confirmed that an A signal was present
in plasma, and that A42 decreased as the A-PET
signal increased. We also explored levels of ApoE
[90], ApoJ [91], inflammatory markers [92], and
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Table 12
Number of lifestyle assessments
Lifestyle Assessment Collection, months∗
Lifestyle 0 18 36 54 72 90 108 126
Assessment
Self-report PA 1,747 1,167 851 701 481 387 326 222
Objective PA 248 33 195 120 86 35 82 -
Diet (CCV FFQ)# 1,905 - 1,066 - 575 - 363 -
Self-report Sleep∧ 616 498 360 198 581 441 377 307
∗Corresponds to cognitive assessment timepoint (month 0 = baseline). #Data collected at alternating timepoints. ∧Sleep measures were
administered to Inception cohort participants from 72 months onwards, and to Enrichment participants from baseline onwards. CCV FFQ,
Cancer Council of Victoria Food Frequency Questionnaire; PA, physical activity.
micro-RNA [93]. New A immunoassays showed
improved performances [94–96] but the combina-
tion of immunoprecipitation and mass spectrometry
proved to have exceptional performance [97], equiv-
alent to CSF assays. Notably, measurement of the
natural history of plasma A change, via one of the
new immunoassays, suggests that the trajectory of
plasma A change mirrors brain A-amyloid accu-
mulation as measured by PET, with a rapid phase of
plasma change observable up to 6 years prior to the
rapid phase of brain A-amyloid accumulation [96].
CSF and plasma A42 are in equilibrium, and are
expected to show changes earlier than A-PET since
the dynamic range of CSF change is greatest at the
lower ranges of A-PET.
Proteomic [98], lipidomic [99] and metabolomic
approaches are now being explored. Moreover, func-
tional assays of mononuclear cell phagocytosis have
indicated that defects in the innate immune response
could play a role in AD [100], confirming indepen-
dent genome-wide association study (GWAS) results
obtained by others.
Cerebrospinal fluid biomarkers: Aβ, tau,
neurofilament light chain
CSF for analysis has to date been donated by 262
subjects, with 242 of these individuals having also
undergone A-amyloid imaging (Table 11). At the
time of writing, we have collected CSF at two time-
points from 109 subjects, and at three timepoints from
33 subjects.
Strong concordance has been observed between
CSF markers (A42, tau, and pTau181) and PET-A-
amyloid status, as measured by the Roche Elecsys and
INNOtest assays [30, 31]. A high correlation of CSF
biomarkers on the AlzBio3 and EUROIMMUNE
platforms has also been reported [101]. Method-
ologically, no difference in these biomarkers was
observed from CSF collected using gravity or aspira-
tion techniques [102]. Moreover, CSF neurofilament
light chain (NfL), a non-specific marker of neuronal
degradation, has been shown to correlate with both
clinical performance and neuropathologic changes,
including reduced cortical grey matter volume, but
did not correlate with A-amyloid burden [103].
Thresholds for abnormal CSF levels of A42, tau
and pTau, compared to a PiB SUVR of 1.5, have been
calculated using the INNOtest [30]. Updated thresh-
olds are presented here using a lower PiB SUVR
threshold of 1.4, and for an updated version of the
INNOtest, which controls the temperature of the
experiment at 25ºC. Using a rank based approach (0.1
fractile for A42 and 0.9 fractile for tau and pTau181)
in a larger cohort of N = 115 CN PET-amyloid neg-
ative participants, with tau data age bracketed, the
normal reference ranges are tau < 303.5 pg/mL (60–
70 years); 378.7 pg/mL (> 70 years), pTau181
< 59.2 pg/mL (60–70 years); 73.8 pg/mL (>70 years),
and A42 > 656.0 pg/mL (> 60 years). A different
set of cut points applies to the Elecsys platform:
using optimisation of Youden’s index, based on a
cohort of 202 participants, the normal thresholds
are for A42 > 1054 pg/mL, tau < 213 pg/mL, and
pTau181 < 21.3 pg/mL [31].
Lifestyle and environmental risk factors
The number of lifestyle assessments completed
at each timepoint is shown in Table 12. The vast
majority of CN and MCI participants completed self-
report measures of physical activity (PA), diet and
sleep at each timepoint (of note, diet was assessed at
alternating timepoints, and sleep measures were first
administered to Inception cohort participants at the
72-month follow-up but to Enrichment cohort partic-
ipants from baseline). Objective measures of PA were
collected via actigraphy from a subset of Perth-based
CN participants as the foundation of two consecutive
PhD student projects.
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With detailed lifestyle data emerging from the
cohort, AIBL is providing an exceptional opportu-
nity to examine the relationship of PA, diet and
sleep to cognitive, neuroimaging and fluid biomarker
outcomes, as well as to investigate targeted genetic
factors that may influence these relationships. Cross-
sectional relationships between habitual PA levels
and various cognitive and brain health markers have
been reported. Objectively measured PA intensity
was linked to better performance on cognitive tasks
assessing executive function [104]. Moreover, self-
reported PA was found to be associated with lower
levels of brain A-amyloid in carriers of the APOE 4
allele [53] and larger hippocampal volume in BDNF
Val/Val homozygotes [75].
The AIBL study was first to show that adherence
to a healthy Mediterranean-style diet is more strongly
associated with less decline in executive function
among APOE 4 carriers [105], and is associated with
a slower rate of A-amyloid accumulation in cogni-
tively unimpaired older adults irrespective of APOE
4 status [106]. We have also reported cross-sectional
associations, in CN older adults, between carbohy-
drate intake and cognitive function, with specific
cognitive domains affected in an APOE genotype-
dependent manner [107], as well as between dietary
protein intake and brain A-amyloid burden, with
higher protein intake associated with less likelihood
of A + status [108].
Insights into the relationship between sleep and
brain A have also been attained, with increased time
to fall asleep (sleep onset latency) associated with
higher brain A-amyloid [109], revealing a poten-
tial target for AD prevention strategies. Furthermore,
the multidisciplinary nature of AIBL has enabled
the first report of genetic variations in Aquaporin-
4 (AQP4) impacting the relationship between sleep
and brain A-amyloid [54]. Aquaporin-4 proteins are
water channel proteins, located primarily in the sub-
pial and perivascular end-feet of astrocytic processes,
which play a role in the brain’s night-time ‘house-
keeping’ system. This system clears waste including
A-amyloid and is postulated to function almost
entirely during sleep [110]. Our study showed that
individuals with particular genetic variations in AQP4
are susceptible to high brain A-amyloid levels if
they experience poor sleep [54]. These findings sug-
gest such individuals might benefit most, in terms of
reduced AD risk, from an intervention to improve
their sleep, bringing personalized strategies for AD
prevention a step closer.
Genetics
Table 13 details the genetic analyses undertaken on
AIBL samples to date. Samples from all 2359 par-
ticipants have undergone APOE genotyping, whilst
subsets have either undergone or are, at the time of
submission, undergoing genome-wide SNP, whole
exome sequencing and cross-sectional and longi-
tudinal genome-wide peripheral DNA methylation
analyses. These data have contributed to research
across all areas of AIBL, providing important genetic
covariates to individual studies or furthering the
understanding of key genetic variables that impact
disease presentation and progression.
AIBL has contributed to the understanding of how
individual genes [47, 67, 76, 77, 111–115] make
variable contributions to cognitive decline in the pre-
clinical and prodromal stages of AD. This has been
extended to enhanced understanding of accumulative
genetic contributions and whether genetic profiles
for risk and progression differ. In AIBL, polygenic
risk scores (PRS) weighted by AD-risk effect sizes
were dependent on the presence of the APOE 4
allele [51]. Moreover, the association, with cognitive
decline, of genetic factors that are not major AD-risk
genes, such as BDNF and KIBRA, led to the devel-
opment of a cognitive-gene risk profile [52]. This
profile was able to identify twice as many individu-
als at risk of preclinical AD-related cognitive decline
than APOE 4-BDNF Met66 interaction alone. Fur-
ther, this profile identified that genetic variation in
genes (e.g., KL; Klotho) that were not independently
associated with preclinical AD cognitive decline, in
AIBL, contributed to delineating these risk groups.
Table 13
Number of genetic analyses conducted by technique
Genetic Analysis
APOE Genome-Wide Whole Exome Genome-Wide
SNP∗ Sequencing Methylation∗
N 2,359 1,357 500 726
∗Samples for both genome-wide SNP and genome-wide methylation analysis are currently being expanded. APOE,
Apolipoprotein E; SNP, single nucleotide polymorphism (976,713 SNPs analyzed).
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These studies were further expanded to the devel-
opment of a novel PRS that incorporated weighting
by effect sizes associated with decline in episodic
memory [50]. As opposed to the AD-risk weighted
PRS, this novel PRS was associated with cognitive
decline both in the presence and absence of APOE
4.
AIBL genomics has also contributed further kno-
wledge to the association of genetic markers with
both PET-A-amyloid status and MRI volumetrics
[51, 76, 77, 116, 117] and, in collaboration with AIBL
lifestyle researchers, has helped uncover genetic
underpinnings of lifestyle-phenotype relationships,
with a particular focus on APOE and BDNF and their
interaction with PA [53, 75], diet [105, 106], and sleep
[109]. This has been expanded to investigate a pri-
ori candidates, such as variation in AQP4 [54]. This
study, as stated above, suggests that genetic variation
in AQP4 moderates the relationship between sleep
and brain A-amyloid levels. Collectively, these
studies emphasize the importance of continued study
of gene-lifestyle interactions, and in turn a focus
on lifestyle genomics, in AD, which could lead to
the development and implementation of personalized
strategies for AD prevention.
Strong collaborations, external to AIBL, have also
seen AIBL contribute significantly to large multi-
center genetic studies that have shed further light on
genetic and epigenetic factors. These have suggested
a more oligogenic rather than polygenic structure to
AD-risk [118] and have provided insights into the
contribution of peripheral genome-wide methylation
across neurodegenerative disease.
Data harmonization and sharing
AIBL data have been provided to the Global Alz-
heimer’s Association Interactive Network (GAAIN),
and software installed, thereby enabling GAAIN
users to interrogate metadata and receive cohort
summaries, whereupon users can request further
information (and biofluid samples; blood and CSF) if
needed by submitting an Expression of Interest (EoI).
This mechanism ensures worldwide sharing and uti-
lization of AIBL data (and biofluid samples) and
complements the existing framework whereby AIBL
imaging scans and demographic data are available
on the ADNI LONI (Laboratory of Neuro Imaging,
University of Southern California) website for free
download and use by researchers worldwide. Up to
3 August 2019, LONI/ GAAIN data applications had
been received from over 120 companies, more than
2,000 organizations/institutes/departments, and over
3,500 individuals, spanning 81 countries. Moreover,
hundreds of EoIs from academic and industry-based
individuals have been approved resulting in further
data and biofluid sample sharing. Data will also be
provided to the National Institute on Aging-funded
ADOPIC (Alzheimer’s Dementia Onset and Pro-
gression in International Cohorts) project which will
harmonise data from the AIBL, ADNI, Washington
University, St. Louis, and University of Washington,
Seattle, cohorts to determine factors which influence
cognitive decline in AD.
Capacity building
The AIBL study framework has been responsible
for training researchers and clinicians of the future, by
supporting multiple Honours and MSc projects, more
than 25 PhD projects, as well as over 15 clinical place-
ment students. Moreover, the study framework and/or
data have been used to successfully obtain funding
from the National Institutes of Health (NIH), and
the National Health and Medical Research Council
(Australia’s peak funding body for medical research)
as well as various philanthropic and non-government
entities including The Yulgilbar Foundation and the
Australian Alzheimer’s Research Foundation.
DISCUSSION
The AIBL Study has collected up to 8 timepo-
ints of data at 18-month intervals in over 2350
participants, yielding a current database of 8592
person-contact years (as of 10 April 2019). The mul-
ticenter, multidisciplinary approach and engagement
of A-amyloid-PET imaging from the outset has
enabled AIBL researchers to make world-class con-
tributions to understanding the natural history of AD
progression.
Using data from the AIBL cohort, the very slow
accumulation rate of AD-related pathologic change
has been calculated [45, 46], the diagnostic and prog-
nostic utility of A-amyloid imaging [44] have been
confirmed, and a wide window of opportunity for
prevention trials has been identified. This vital, new
knowledge has been translated to the design and
implementation of trials to prevent progression to
dementia from AD.
Indeed, the cohorts and technologies provided by
AIBL have facilitated early intervention trials in Aus-
tralia and worldwide. AIBL has enabled Australia
to form a large single site for participation in the
C. Fowler et al. / Progress and Observations from the AIBL Study 461
Anti-Amyloid therapy in Asymptomatic AD (A4)
trial, and to be a major contributor to the Dom-
inantly Inherited Alzheimer Network (DIAN) and
DIAN Therapy studies outside of the USA. More-
over, through tracer validation, and first in human
studies with colleagues in Japan and the USA, AIBL
researchers have played a key role in the recent
development of PET scans for tau aggregates. Serial
tau imaging has been added to the investigations in
a subset of AIBL participants, and this new tech-
nology promises further important insights into the
development of AD, potentially opening the door to
new therapeutic approaches. New AIBL-developed
PET imaging analysis methods and promising blood
biomarkers have also generated international patents.
To date, AIBL has enabled several promising
blood biomarker candidates and panels to be iden-
tified that include A-amyloid species and ApoE
levels, unique inflammatory and lipid-related com-
pounds, genomics, and micro RNA markers from
exosomes [87, 90, 93, 97, 119, 120]. Another blood
biomarker developed from the AIBL cohort that cor-
relates closely with A-amyloid PET classification
is under licensing negotiation with a pharmaceutical
company.
AIBL has provided important insights into the
cognitive, genetic, and A-related changes that lead
to AD. Assessments of visual learning and work-
ing memory in both preclinical and prodromal AD
revealed A-amyloid-related cognitive decline [25,
61], which was increased further in the presence of
the APOE 4 allele [62]. Variation in the BDNF
Val66Met polymorphism, was also shown to substan-
tially influence the course of cognitive decline, and
clinical disease progression [47]. Moreover, seminal
new work from the AIBL cohort has shown that the
earliest and most severe cognitive impairment in pre-
clinical AD manifests as a reduction in learning, as
opposed to impairment in memory [69]. The learn-
ing deficit was much more evident than the memory
deficit in the preclinical AD subjects. This may reflect
damage to those areas of the Default Mode Network
where A-amyloid is seen to first begin accumulat-
ing, i.e., in the precuneus, posterior cingulate and
frontal cortices.
Lifestyle correlation with cognitive and neuroim-
aging biomarker change over time has provided sup-
port for PA and dietary modification to slow AD
development. This work has highlighted the impor-
tance of PA intensity as well as volume for cognitive
performance and brain health [53, 104], and has
demonstrated the ability of PA and a healthy Med-
iterranean-style diet to mitigate the negative effects
of APOE 4 carriage on cognitive decline and A-
amyloid accumulation [53, 105, 106]. Intervention
studies are required to confirm the impact of PA and
a Mediterranean-style diet on the accumulation of AD
pathology in the brain. AIBL has also provided novel
insights into the relationship between sleep and A-
amyloid; revealing associations between longer sleep
onset latency and higher brain A-amyloid [109], as
well as a moderating effect of genetic variation in
Aquaporin-4 on the relationship between sleep and
brain A-amyloid burden [54]. Collectively, these
works have revealed potential targets for AD pre-
vention studies, as well as bringing personalized
strategies for AD prevention, based on genotype, a
step closer.
New genetic factors that modulate rate of cognitive
decline prior to dementia have been identified and sig-
nificant contributions have been made to achieving a
greater understanding of the genetic architecture of
both AD risk and progression, particularly how these
may differ both in terms of structure and contribut-
ing factors. In addition to the APOE 4 allele [45]
and the BDNF Met66 allele [47] mentioned above,
AIBL has also demonstrated that specific genetic pro-
files [52], and a novel PRS [50], are all associated
with faster cognitive decline in individuals with pre-
clinical or prodromal AD. Many of these findings
have been used in the design of early intervention tri-
als such as the NIH- and industry-funded A4 Study
[49]; AIBL investigators are contributing up to 150
participants to this trial. Further exploration of the
genetic architecture of AD risk and progression will
also be possible as AIBL extends both its genetic
and epigenetic analyses. Such exploration has already
seen AIBL contribute to large multi-center studies
reporting that AD risk is likely more oligogenic than
polygenic in structure [118].
AIBL continues to make significant contributions
to international efforts focused on improving the
understanding of AD pathogenesis and diagnosis, as
well as contributing to the design of both pharma-
cologic and non-pharmacologic intervention studies
aimed at preventing dementia due to AD. AIBL data
sharing has occurred via the ADNI LONI website,
GAAIN, the US-based Pre-clinical AD Consortium
and an EU consortium (CONNECT-ND). AIBL data
are also pooled with ADNI, Japan-ADNI, DIAN,
the Adult Children Study, the Wisconsin Registry
for Alzheimer’s Prevention, and other initiatives to
increase statistical power, as well as a variety of Euro-
pean consortia through the European Union Joint Pro-
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gramme – Neurodegenerative Disease Research
(JPND). Data will also be provided to the Nat-
ional Institute on Aging-funded ADOPIC project.
Collectively, these approaches have ensured that
AIBL data have been shared, across 81 countries,
with researchers based in academia and industry.
Whilst it is evident that AIBL has made significant
contributions to understanding the natural history of
AD, and characterizing factors which impact the rate
at which AD phenotypes develop, there are some
limitations that should be noted. For example, the
relatively high age of CN participants at baseline pre-
cludes direct quantification of the earliest AD-related
changes. Only a subset of participants provided CSF
samples, with few follow-up samples collected to
date, which limits longitudinal biomarker analysis in
this biofluid. Moreover, the cohort is predominantly
Caucasian with a relatively high level of education,
which limits the generalizability of our findings.
Despite these limitations, AIBL will continue to
contribute to addressing the major challenges ahead
for our field, which include, defining the earliest
cut-points for onset of preclinical AD, developing
practical algorithms for predicting rates of progres-
sion, and determining the generalizability of current
findings into ethnically/ socially diverse populations.
Moreover, the attribution of degrees of cognitive
impairment, and the differential diagnosis of AD
from the two major co-morbidities of FTD/ hip-
pocampal sclerosis (TAR DNA-binding protein of
about 43 kDa (TDP-43) pathology) and small ves-
sel involvement in cerebrovascular disease in the
elderly population, remain unresolved. Once these
issues have been addressed, the optimal approach to
designing primary and secondary prevention trials
will become apparent.
In summary, AIBL is at the forefront of AD
research. AIBL data have contributed to the devel-
opment of new diagnostic criteria for AD that permit
earlier and more accurate diagnosis [121–123], and
to the design of early intervention trials aimed
at preventing the development of dementia from
AD. AIBL has united AD researchers across Aus-
tralia and as part of worldwide ADNI, AIBL has
greatly increased Australian collaboration with inter-
national AD research groups. AIBL infrastructure
is now also supporting recruitment for academic
and industry-funded therapy trials. Further refine-
ment and validation of blood biomarkers for AD will
be undertaken, genetic and epigenetic contributions
and profiles for onset and progression will be devel-
oped, lifestyle influences on cognition and AD will
be prospectively tracked, and more early intervention
studies will be launched. Moreover, with over 340
publications to date and 2500 citations per year, the
increasing value, impact and productivity of AIBL
with time is apparent, as is the increasing value of
accumulating longitudinal data.
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Blennow K, Schöll M, Zetterberg H, Ellis KA, Bush AI,
Rowe CC, Villemagne VL, Ames D, Masters CL, Aars-
land D, Powell J, Lovestone S, Martins R, Hye A (2019)
A plasma protein classifier for predicting amyloid burden
for preclinical Alzheimer’s disease. Sci Adv 5, eaau7220.
[99] Lim WLF, Huynh K, Chatterjee P, Martins I, Jayawardana
KS, Giles C, Mellett NA, Laws SM, Bush AI, Rowe CC,
Villemagne VL, Ames D, Drew BG, Masters CL, Meikle
PJ, Martins RN (2020) Relationships between plasma
lipids species, gender, risk factors, and Alzheimer’s dis-
ease. J Alzheimers Dis 76, 303-315.
[100] Gu BJ, Huang X, Ou A, Rembach A, Fowler C, Avula
PK, Horton A, Doecke JD, Villemagne VL, Macaulay SL,
Maruff P, Fletcher EL, Guymer R, Wiley JS, Masters CL
(2016) Innate phagocytosis by peripheral blood monocytes
is altered in Alzheimer’s disease. Acta Neuropathol 132,
377-389.
[101] Doecke JD, Rembach A, Villemagne VL, Varghese S,
Rainey-Smith S, Sarros S, Evered LA, Fowler CJ, Per-
tile KK, Rumble RL, Trounson B, Taddei K, Laws SM,
Macaulay SL, Bush AI, Ellis KA, Martins R, Ames D,
Silbert B, Vanderstichele H, Masters CL, Darby DG, Li
QX, Collins S, AIBL Research Group (2018) Concordance
between cerebrospinal fluid biomarkers with Alzheimer’s
disease pathology between three independent assay plat-
forms. J Alzheimers Dis 61, 169-183.
[102] Rembach A, Evered LA, Li QX, Nash T, Vidaurre L,
Fowler CJ, Pertile KK, Rumble RL, Trounson BO, Maher
S, Mooney F, Farrow M, Taddei K, Rainey-Smith S, Laws
SM, Macaulay SL, Wilson W, Darby DG, Martins RN,
Ames D, Collins S, Silbert B, Masters CL, Doecke JD, the
AIBL Research Group (2015) Alzheimer’s disease cere-
brospinal fluid biomarkers are not influenced by gravity
drip or aspiration extraction methodology. Alzheimers Res
Ther 7, 71.
[103] Dhiman K, Gupta VB, Villemagne VL, Eratne D, Gra-
ham PL, Fowler C, Bourgeat P, Li QX, Collins S, Bush
AI, Rowe CC, Masters CL, Ames D, Hone E, Blennow
K, Zetterberg H, Martins RN (2020) Cerebrospinal fluid
neurofilament light concentration predicts brain atrophy
and cognition in Alzheimer’s disease. Alzheimers Dement
(Amst) 12, e12005.
[104] Brown BM, Peiffer JJ, Sohrabi HR, Mondal A, Gupta VB,
Rainey-Smith SR, Taddei K, Burnham S, Ellis KA, Szoeke
C, Masters CL, Ames D, Rowe CC, Martins RN, AIBL
research group (2012) Intense physical activity is asso-
ciated with cognitive performance in the elderly. Transl
Psychiatry 2, e191.
[105] Gardener SL, Rainey-Smith SR, Barnes MB, Sohrabi HR,
Weinborn M, Lim YY, Harrington K, Taddei K, Gu Y,
Rembach A, Szoeke C, Ellis KA, Masters CL, Macaulay
SL, Rowe CC, Ames D, Keogh JB, Scarmeas N, Martins
RN (2015) Dietary patterns and cognitive decline in an
Australian study of ageing. Mol Psychiatry 20, 860-866.
[106] Rainey-Smith SR, Gu Y, Gardener SL, Doecke JD, Ville-
magne VL, Brown BM, Taddei K, Laws SM, Sohrabi HR,
Weinborn M, Ames D, Fowler C, Macaulay SL, Maruff
468 C. Fowler et al. / Progress and Observations from the AIBL Study
P, Masters CL, Salvado O, Rowe CC, Scarmeas N, Mar-
tins RN (2018) Mediterranean diet adherence and rate
of cerebral Abeta-amyloid accumulation: Data from the
Australian Imaging, Biomarkers and Lifestyle Study of
Ageing. Transl Psychiatry 8, 238.
[107] Gardener SL, Rainey-Smith SR, Sohrabi HR, Weinborn
M, Verdile G, Fernando W, Lim YY, Harrington K, Burn-
ham S, Taddei K, Masters CL, Macaulay SL, Rowe CC,
Ames D, Maruff P, Martins RN, AIBL Research Group
(2017) Increased carbohydrate intake is associated with
poorer performance in verbal memory and attention in an
APOE genotype-dependent manner. J Alzheimers Dis 58,
193-201.
[108] Fernando WMADB, Rainey-Smith SR, Gardener SL,
Villemagne VL, Burnham SC, Macaulay SL, Brown BM,
Gupta VB, Sohrabi HR, Weinborn M, Taddei K, Laws
SM, Goozee K, Ames D, Fowler C, Maruff P, Masters
CL, Salvado O, Rowe CC, Martins RN, AIBL Research
Group (2018) Associations of dietary protein and fiber
intake with brain and blood amyloid-beta. J Alzheimers
Dis 61, 1589-1598.
[109] Brown BM, Rainey-Smith SR, Villemagne VL, Weinborn
M, Bucks RS, Sohrabi HR, Laws SM, Taddei K, Macaulay
SL, Ames D, Fowler C, Maruff P, Masters CL, Rowe
CC, Martins RN, AIBL Research Group (2016) The rela-
tionship between sleep quality and brain amyloid burden.
Sleep 39, 1063-1068.
[110] Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M,
O’Donnell J, Christensen DJ, Nicholson C, Iliff JJ, Takano
T, Deane R, Nedergaard M (2013) Sleep drives metabolite
clearance from the adult brain. Science 342, 373-377.
[111] Lim YY, Laws SM, Villemagne VL, Pietrzak RH, Porter
T, Ames D, Fowler C, Rainey-Smith S, Snyder PJ, Mar-
tins RN, Salvado O, Bourgeat P, Rowe CC, Masters CL,
Maruff P (2016) Abeta-related memory decline in APOE
epsilon4 noncarriers: Implications for Alzheimer disease.
Neurology 86, 1635-1642.
[112] Lim YY, Rainey-Smith S, Lim Y, Laws SM, Gupta V,
Porter T, Bourgeat P, Ames D, Fowler C, Salvado O,
Villemagne VL, Rowe CC, Masters CL, Zhou XF, Mar-
tins RN, Maruff P (2017) BDNF Val66Met in preclinical
Alzheimer’s disease is associated with short-term changes
in episodic memory and hippocampal volume but not
serum mBDNF. Int Psychogeriatr 29, 1825-1834.
[113] Lim YY, Villemagne VL, Laws SM, Ames D, Pietrzak
RH, Ellis KA, Harrington KD, Bourgeat P, Salvado O,
Darby D, Snyder PJ, Bush AI, Martins RN, Masters
CL, Rowe CC, Nathan PJ, Maruff P, Australian Imaging,
Biomarkers and Lifestyle (AIBL) Research Group (2013)
BDNF Val66Met, Abeta amyloid, and cognitive decline
in preclinical Alzheimer’s disease. Neurobiol Aging 34,
2457-2464.
[114] Porter T, Burnham SC, Milicic L, Savage G, Maruff P, Lim
YY, Ames D, Masters CL, Martins RN, Rainey-Smith S,
Rowe CC, Salvado O, Groth D, Verdile G, Villemagne
VL, Laws SM (2019) Klotho allele status is not associated
with Abeta and APOE epsilon4-related cognitive decline
in preclinical Alzheimer’s disease. Neurobiol Aging 76,
162-165.
[115] Porter T, Burnham SC, Milicic L, Savage G, Maruff P,
Sohrabi HR, Peretti M, Lim YY, Weinborn M, Ames D,
Masters CL, Martins RN, Rainey-Smith S, Rowe CC, Sal-
vado O, Groth D, Verdile G, Villemagne VL, Laws SM
(2019) COMT val158met is not associated with Abeta-
amyloid and APOE epsilon4 related cognitive decline in
cognitively normal older adults. IBRO Rep 6, 147-152.
[116] Lim YY, Williamson R, Laws SM, Villemagne VL,
Bourgeat P, Fowler C, Rainey-Smith S, Salvado O, Martins
RN, Rowe CC, Masters CL, Maruff P, AIBL (2017) Effect
of APOE genotype on amyloid deposition, brain volume,
and memory in cognitively normal older individuals. J
Alzheimers Dis 58, 1293-1302.
[117] Vacher M, Porter T, Villemagne VL, Milicic L, Peretti M,
Fowler C, Martins R, Rainey-Smith S, Ames D, Masters
CL, Rowe CC, Doecke JD, Laws SM (2019) Validation
of a priori candidate Alzheimer’s disease SNPs with brain
amyloid-beta deposition. Sci Rep 9, 17069.
[118] Zhang Q, Sidorenko J, Couvy-Duchesne B, Marioni RE,
Wright MJ, Goate AM, Marcora E, Huang KL, Porter T,
Laws SM, Australian Imaging Biomarkers and Lifestyle
(AIBL) Study; Sachdev PS, Mather KA, Armstrong NJ,
Thalamuthu A, Brodaty H, Yengo L, Yang J, Wray
NR, McRae AF, Visscher PM (2020) Risk prediction
of late-onset Alzheimer’s disease implies an oligogenic
architecture. Nat Commun 11, 4799.
[119] Rembach A, Faux NG, Watt AD, Pertile KK, Rumble
RL, Trounson BO, Fowler CJ, Roberts BR, Perez KA,
Li QX, Laws SM, Taddei K, Rainey-Smith S, Robertson
JS, Vandijck M, Vanderstichele H, Barnham KJ, Ellis KA,
Szoeke C, Macaulay L, Rowe CC, Villemagne VL, Ames
D, Martins RN, Bush AI, Masters CL, AIBL research
group (2014) Changes in plasma amyloid beta in a longitu-
dinal study of aging and Alzheimer’s disease. Alzheimers
Dement 10, 53-61.
[120] Faux NG, Rembach A, Wiley J, Ellis KA, Ames D, Fowler
CJ, Martins RN, Pertile KK, Rumble RL, Trounson B,
Masters CL, AIBL Research Group; Bush AI (2014)
An anemia of Alzheimer’s disease. Mol Psychiatry 19,
1227-1234.
[121] Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo
JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bate-
man R, Cappa S, Crutch S, Engelborghs S, Frisoni GB,
Fox NC, Galasko D, Habert MO, Jicha GA, Nordberg A,
Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S,
Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ,
Schneider L, Stern Y, Scheltens P, Cummings JL (2014)
Advancing research diagnostic criteria for Alzheimer’s
disease: The IWG-2 criteria. Lancet Neurol 13, 614-629.
[122] Albert MS, DeKosky ST, Dickson D, Dubois B, Feld-
man HH, Fox NC, Gamst A, Holtzman DM, Jagust
WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B,
Phelps CH (2011) The diagnosis of mild cognitive impair-
ment due to Alzheimer’s disease: Recommendations from
the National Institute on Aging-Alzheimer’s Association
workgroups on diagnostic guidelines for Alzheimer’s dis-
ease. Alzheimers Dement 7, 270-279.
[123] Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft
S, Fagan AM, Iwatsubo T, Jack CR, Jr., Kaye J, Montine
TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern
Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M,
Wagster MV, Phelps CH (2011) Toward defining the pre-
clinical stages of Alzheimer’s disease: Recommendations
from the National Institute on Aging-Alzheimer’s Associ-
ation workgroups on diagnostic guidelines for Alzheimer’s
disease. Alzheimers Dement 7, 280-292.
